Odimma
Odimma Therapeutics is a French biotech company specializing in personalized cancer immunotherapy. Their innovative platform, ODI-2001, utilizes synthetic DNA technology combined with adjuvants (MVA and anti-CTLA4) to harness the patient's own immune system to target unique tumor neoantigens. This approach aims to induce a powerful cellular immune response against specific tumor markers, offering a game-changer in immuno-oncology for hard-to-treat cancers like melanoma, colorectal, and breast cancer. The company leverages AI for neoantigen prediction and aims to provide tailored pharmaceutical preparations with a favorable economic profile to maximize patient benefit.
Odimma
Odimma Therapeutics is a French biotech company specializing in personalized cancer immunotherapy. Their innovative platform, ODI-2001, utilizes synthetic DNA technology combined with adjuvants (MVA and anti-CTLA4) to harness the patient's own immune system to target unique tumor neoantigens. This approach aims to induce a powerful cellular immune response against specific tumor markers, offering a game-changer in immuno-oncology for hard-to-treat cancers like melanoma, colorectal, and breast cancer. The company leverages AI for neoantigen prediction and aims to provide tailored pharmaceutical preparations with a favorable economic profile to maximize patient benefit.
TL;DR
What they do: Personalised DNA-based cancer immunotherapy platform (ODI-2001) combining synthetic neoantigen vectors with adjuvants
Headquarters: Illkirch / Strasbourg, Alsace, France
Founded: 2017
Stage / funding: Seed / ~€5M reported
Founders / leadership: Jessica Matta (co-founder/CEO), Jean Marc Limacher, MD (co-founder, Chairman/CMO)
Company Overview
Problem Domain
Personalised cancer immunotherapy for hard-to-treat tumours (e.g., melanoma, colorectal, breast).
Founded
2017
Industry
Biotechnology
Funding Track Record
≈€5M
Reported investors include Capital Grand Est, Alsace Business Angels, Angels Santé, and Bpifrance
Investor Signal
“Regional angel and public investors (Capital Grand Est, Alsace Business Angels, Angels Santé, Bpifrance)”